HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Animal alternative tests

This article was originally published in The Rose Sheet

Executive Summary

Interagency Coordinating Committee on the Validation of Alternative Methods posts additional data on Hen's Egg Test - Chorioallantoic Membrane on its Web site Nov. 16. Addendum includes in vitro data for substances tested in CEC, in vitro and in vivo comparison of ocular irritancy classification of substances tested in CEC and in vivo and in vitro comparison of ocular irritancy classification, data sorted by substance for IS(B) analysis method. The National Interagency Center for the Evaluation of Alternative Toxicological Methods and ICCVAM recently posted draft background review documents on four alternative ocular irritancy tests, including HET-CAM, Bovine Corneal Opacity and Permeability, Isolated Chicken Eye and the Isolated Rabbit Eye (1"The Rose Sheet" Nov. 15, 2004, p. 5). Agencies are seeking comments on the documents by Dec. 30, which will be addressed during a meeting Jan. 11-12 in Bethesda, Md...

You may also be interested in...



Ocular Irritation Test Recommendations Outlined By ICCVAM

Optimization and validation studies using a standardized test method protocol should be conducted before four in vitro test methods evaluating severe eye irritants and corrosives are routinely used for regulatory hazard classification and labeling in a regulatory tiered testing strategy, the Interagency Coordinating Committee for the Validation of Alternative Methods says

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel